Answers are grounded in this paper and cite their sources.
The article presents two clinical cases of secondary treatment-related haemoblastosis – treatment-related myelodisplastic syndrome (t-MDS)/treatment-related acute myeloid leukaemia (AML) – t-MDS/t-AML, compared to the data of other world's investigators. Two boys with primary diagnosed acute lymphoblastic leukaemia (ALL) were treated according to the program ALL IC-BFM-2002, depending upon their belonging to intermediate (IRTG) and high-risk treatment groups (HRTG). The secondary MDS associated with monosomy 7 developed in the patient of the intermediate risk group, which was subsequently transformed to secondary AML. After allogenic transplantation of haemopoetic cells of umbilical cord blood, it appeared that the post-transplant complications developed, which caused death of the patient. In another boy from the high-risk group, the secondary AML associated with translocation t(9.11) (p22; q23) was diagnosed. He was provided with allogenic transplantation of haemopoetic cells as well. The patient has been in clinical-haematological remission of ALL for 77 months and clinical-haematological remission of t-AML — 49 months. The t-MDS/t-AML are registered amid supportive chemotherapy of ALL after 20 months in males with chromosome anomalies, predisposed to progress during standard chemotherapy and severe infectious toxic complications associated with cytopenia. The transplantation of haemopoetic cells presents the only treatment regimen for patients with t-MDS/t-AML.
No takes yet. Share an insight, caveat, or question.
Дорош et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: